Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
about
Management of antipsychotic-related weight gainGenomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsEtiology of cardiovascular disease in patients with schizophrenia: current perspectivesReview of the evidence: prevalence of medical conditions in the United States population with serious mental illnessDetection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse modelsPharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineMolecular substrates of schizophrenia: homeostatic signaling to connectivityOnset of obstructive sleep apnea after initiation of psychotropic agents.Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.A behavioral weight-loss intervention in persons with serious mental illnessCardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial.Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluationRelative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationImpact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams.The Prevalence of Metabolic Syndrome and Its Related Factors among Adults in Palestine: A Meta-Analysis.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationEndothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia.Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disordersMetabolic Effects of Antidepressant TreatmentAssociation of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia.Mortality in schizophrenia: clinical and serological predictorsIncreased serum brain-derived neurotrophic factor in male schizophrenic patients with metabolic syndrome.Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum DisordersThe concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice.Prevalence of night eating in obese individuals with schizophrenia and schizoaffective disorder.Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.The contribution of abdominal obesity and dyslipidemia to metabolic syndrome in psychiatric patients.Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study.The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia.Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Clinical pharmacology and vascular risk.Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia
P2860
Q24610124-ED3155DC-4FC5-4187-B492-E6AF9CDD92FEQ24630309-4EBCE88A-3C56-4A88-9AA8-319D53F18745Q26778485-2A8D3DFA-6F73-4026-B986-E05D99A8CFC7Q26849474-990C9084-80C5-434E-AE71-68E7042FC0E1Q26864342-20487BB6-33A1-44F2-9821-A36C30D60703Q26866254-508114DB-C247-4A2C-B642-B7EB488E5E70Q27692023-FE3C5067-E445-4B9F-8ECB-F2798EAFA454Q28543222-FF590174-6D9B-4875-941F-7057708B977FQ30383611-929699A3-4DBD-4D46-A4E2-A13BBDDB0D55Q30443964-0C1BDC15-5484-448D-9E42-FAE83A7D90DFQ30459096-22218217-14B4-4945-A941-E450C78CFAC0Q30542864-5F865675-DC86-495B-B726-751029FC7751Q30949176-79C4DE3D-808B-435B-8ECF-BA3BE6C6CBF9Q31145823-D453B56E-E33A-4CD1-B1AF-50C50DB1AB9BQ33257886-AA0E5A13-AA07-4173-BF11-26EEB69FA3DEQ33369547-1A329F33-D1A5-4752-A7ED-1F2FC952AD72Q33371995-2AAD9FCF-5DC6-46CF-A023-5373C8CA57E2Q33519730-9E7C0C18-321B-498D-91EB-6E1DB7F24DE9Q33539405-DCFDBC1C-4AD1-4A6E-ADB0-6C2A3659C358Q33559826-7E83F160-79AB-4E55-9659-698C3BA5F953Q33622056-080A488E-6BA9-423E-91C3-9AF7780F1F4CQ33688651-B6C68E19-564A-4904-AC62-070CA63D6280Q33703032-6454CB22-A61A-4189-A633-7C13425FA66CQ33712365-A5890834-19E0-4C03-A67E-AB7BA38CC75BQ33717601-C19E2D34-75AC-4609-B5BD-3FAD413D63EEQ33762540-360BD45F-6156-4A14-BABF-4E0AE7BCD131Q33765625-831B1C8B-A26B-4A68-AC99-0DFF869D3172Q33802927-364694C6-FAE5-401F-8789-1C9590CF66FAQ33849136-094445D7-9A89-476E-8413-2F52331B4543Q33850466-CA63FC6B-BAD2-41A5-B0EA-568781094CEAQ33870502-9A99EB7F-7458-4448-84E1-C64389AEF455Q33889282-A0E836E4-AF83-46AA-B66A-9CA095174B97Q33893935-E4E6A01F-765D-416F-8DEA-469533383A13Q33966340-5C20A618-B469-4094-A15F-FC9275C11D39Q33968686-558A57ED-04D9-4FE7-B3FC-FCBD29B017A5Q33972014-8E5D415C-D215-4EB4-9F93-720F78807647Q34006864-5D82331A-7A59-4393-B157-295F407C54F8Q34054063-691C96BC-0FF7-4770-A264-BFF81DD8A63AQ34072168-ABEEF361-5F79-4BE6-ABFF-AFECEA145F1FQ34091872-991A1D1D-371E-4B32-81EE-BAFBF88D9BA5
P2860
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Prevalence of the metabolic sy ...... nal estimates from NHANES III.
@en
Prevalence of the metabolic sy ...... of Intervention Effectiveness
@nl
type
label
Prevalence of the metabolic sy ...... nal estimates from NHANES III.
@en
Prevalence of the metabolic sy ...... of Intervention Effectiveness
@nl
prefLabel
Prevalence of the metabolic sy ...... nal estimates from NHANES III.
@en
Prevalence of the metabolic sy ...... of Intervention Effectiveness
@nl
P2093
P50
P921
P1476
Prevalence of the metabolic sy ...... nal estimates from NHANES III.
@en
P2093
Henry A Nasrallah
Herbert Y Meltzer
John Hsiao
Jonathan M Meyer
Joseph P McEvoy
Sonia M Davis
T Scott Stroup
P356
10.1016/J.SCHRES.2005.07.014
P407
P577
2005-08-30T00:00:00Z